Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.07 +0.34 (+2.00%)

Streaming Delayed Price Updated: 12:55 PM EDT, Jul 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Takeda Announces New Assignments of Directors

June 26, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

June 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

June 22, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

June 21, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

June 21, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

June 18, 2024

Via Benzinga

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

June 18, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 17, 2024

Via Benzinga

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? ↗

June 17, 2024

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.

Via Benzinga

Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies ↗

June 17, 2024

Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes

Via Benzinga

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

June 17, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare ↗

June 15, 2024

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...

Via Talk Markets

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

June 14, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

June 11, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 F-Rated Stocks to Avoid at All Costs in June ↗

June 06, 2024

The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.

Via InvestorPlace

Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report ↗

June 03, 2024

Blackstone reportedly considers sale of Japanese consumer healthcare firm Alinamin Pharmaceutical (previously owned by Takeda) for $1.9B, attracting interest from other firms.

Via Benzinga

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

June 03, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

June 01, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

May 31, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗

May 25, 2024

Via Talk Markets

Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal ↗

May 19, 2024

In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones.

Via Talk Markets

Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement ↗

May 15, 2024

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.

Via Benzinga

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

May 14, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? ↗

May 13, 2024

Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.

Via Benzinga

Why Is AC Immune (ACIU) Stock Up 45% Today? ↗

May 13, 2024

AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.

Via InvestorPlace

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

May 13, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Catalyst's New CEO Has Big Ideas For The Small Biotech ↗

May 10, 2024

Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.

Via Investor's Business Daily

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% ↗

May 09, 2024

Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.

Via Benzinga

TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023 ↗

May 09, 2024

Takeda Pharmaceutical just reported results for the fourth quarter of 2023.

Via InvestorPlace

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

May 09, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.